Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists.

Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.
Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.

Update: June, 2021:  Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa




Therapeutics

Life Sciences

Health Care

Medical Devices

Nanoscope Therapeutics Inc.

Sulagna Bhattacharya

Michael Marquez

Anthony Togba

Samuel Barone

Jean Chang

Jared Stephens

Samarendra Mohanty

The Leadership Team at Nanoscope Therapeutics Inc. is responsible for steering the strategic direction of the company, ensuring the successful development and implementation of its groundbreaking gene therapies. This team oversees clinical trials, regulatory approvals, business development, financial management, and overall corporate strategy to achieve Nanoscope's mission of restoring vision in individuals suffering from retinal degenerative diseases.

Leadership Team

Finance Team

Leadership Team

About

Team members

Other teams at Nanoscope Therapeutics Inc.

Finance Team